LV12990B - Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals - Google Patents

Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals Download PDF

Info

Publication number
LV12990B
LV12990B LVP-03-14A LV030014A LV12990B LV 12990 B LV12990 B LV 12990B LV 030014 A LV030014 A LV 030014A LV 12990 B LV12990 B LV 12990B
Authority
LV
Latvia
Prior art keywords
die
der
und
von
medicaments
Prior art date
Application number
LVP-03-14A
Other languages
English (en)
Latvian (lv)
Inventor
Olaf Weber
Tobias Schlapp
Angela Siegling
Andreas Knorr
Claudia Hirth-Dietrich
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122451A external-priority patent/DE10122451A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of LV12990B publication Critical patent/LV12990B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LVP-03-14A 2000-07-11 2003-02-11 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals LV12990B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs

Publications (1)

Publication Number Publication Date
LV12990B true LV12990B (en) 2003-08-20

Family

ID=26006335

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-03-14A LV12990B (en) 2000-07-11 2003-02-11 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals

Country Status (36)

Country Link
US (1) US6685950B2 (pl)
EP (1) EP1303286B1 (pl)
JP (1) JP5037775B2 (pl)
CN (1) CN1455674B (pl)
AR (1) AR029954A1 (pl)
AT (1) ATE324115T1 (pl)
AU (2) AU2001270631B2 (pl)
BG (1) BG107448A (pl)
CA (1) CA2415397C (pl)
CY (1) CY1105408T1 (pl)
CZ (1) CZ200371A3 (pl)
DE (1) DE50109630D1 (pl)
DK (2) DK1303286T3 (pl)
EE (1) EE200300018A (pl)
ES (1) ES2262663T3 (pl)
FI (1) FI20030037A (pl)
GB (1) GB2381454B8 (pl)
HK (1) HK1054329B (pl)
HR (1) HRP20030096A2 (pl)
HU (1) HUP0400479A3 (pl)
IL (1) IL153643A0 (pl)
LT (1) LT5079B (pl)
LU (1) LU90997B1 (pl)
LV (1) LV12990B (pl)
MA (1) MA26927A1 (pl)
MX (1) MXPA03000279A (pl)
NO (1) NO20030082D0 (pl)
NZ (1) NZ523534A (pl)
PL (1) PL366397A1 (pl)
PT (1) PT1303286E (pl)
RU (1) RU2003104525A (pl)
SE (1) SE0300034L (pl)
SI (1) SI21122A (pl)
SK (1) SK362003A3 (pl)
UY (1) UY26832A1 (pl)
WO (1) WO2002004002A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
EE05680B1 (et) 2000-11-23 2013-10-15 Bavarian Nordic A/S Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
WO2004022729A1 (en) * 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en) 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
AU2002362072A1 (en) * 2001-12-07 2003-06-23 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
AU2003239805B2 (en) * 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
PL1765370T3 (pl) * 2004-07-13 2010-02-26 Aicuris Gmbh & Co Kg Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS
DE602006010902D1 (de) * 2005-11-24 2010-01-14 Aicuris Gmbh & Co Kg Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs
JP5004990B2 (ja) * 2009-03-31 2012-08-22 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3504940C2 (de) * 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
DE59712852D1 (de) * 1996-02-28 2007-07-19 Bayer Healthcare Ag Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
HUP9902438A3 (en) * 1996-03-29 2000-03-28 Bayer Ag Parapoxvirus vectors
HU224308B1 (hu) * 1996-04-15 2005-07-28 Anton Mayr Attenuált, nem immunogén poxvírusokból vagy parapoxvírusokból származó multipotens parapox immunitás-inducerek alkalmazása gyógyszerkészítmények előállítására
SE9700617D0 (sv) * 1997-02-21 1997-02-21 Kjell Alving New composition
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
JP2003517275A (ja) * 1998-11-02 2003-05-27 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 哺乳動物ｖｅｇｆレセプター−２に結合し、これを活性化するオルフウイルスｎｚ２由来の血管内皮細胞増殖因子様タンパク質

Also Published As

Publication number Publication date
US20030021769A1 (en) 2003-01-30
WO2002004002A3 (de) 2002-10-31
AR029954A1 (es) 2003-07-23
HK1054329A1 (en) 2003-11-28
PT1303286E (pt) 2006-08-31
CN1455674B (zh) 2019-03-29
LT5079B (lt) 2003-12-29
MA26927A1 (fr) 2004-12-20
DK1303286T3 (da) 2006-08-28
NZ523534A (en) 2005-02-25
IL153643A0 (en) 2003-07-06
SE0300034L (sv) 2003-03-03
PL366397A1 (pl) 2005-01-24
CA2415397A1 (en) 2002-01-17
CZ200371A3 (cs) 2003-04-16
DK200300015A (da) 2003-03-07
HUP0400479A3 (en) 2006-02-28
WO2002004002A2 (de) 2002-01-17
MXPA03000279A (es) 2004-04-05
EE200300018A (et) 2004-10-15
US6685950B2 (en) 2004-02-03
ATE324115T1 (de) 2006-05-15
GB2381454B8 (en) 2007-10-23
AU2001270631B2 (en) 2005-07-07
JP5037775B2 (ja) 2012-10-03
UY26832A1 (es) 2002-01-31
SI21122A (sl) 2003-08-31
LT2003009A (en) 2003-08-25
DE50109630D1 (de) 2006-06-01
HRP20030096A2 (en) 2005-02-28
SE0300034D0 (sv) 2003-01-10
GB2381454A8 (en) 2007-10-23
LU90997B1 (en) 2003-01-08
GB2381454A (en) 2003-05-07
GB0302630D0 (en) 2003-03-12
NO20030082L (no) 2003-01-08
RU2003104525A (ru) 2004-06-27
EP1303286B1 (de) 2006-04-26
JP2004517807A (ja) 2004-06-17
EP1303286A2 (de) 2003-04-23
AU7063101A (en) 2002-01-21
HK1054329B (zh) 2005-10-07
CA2415397C (en) 2011-04-26
BG107448A (bg) 2003-11-28
GB2381454B (en) 2004-11-24
NO20030082D0 (no) 2003-01-08
ES2262663T3 (es) 2006-12-01
CN1455674A (zh) 2003-11-12
HUP0400479A2 (hu) 2004-06-28
FI20030037A (fi) 2003-03-10
CY1105408T1 (el) 2010-04-28
SK362003A3 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
LV12990B (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
EP0777499A1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE102015111756A1 (de) Rekombinanter Orf-Virus-Vektor
DE102008010954A1 (de) DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
DE102021001841A1 (de) Sensorische Nukleinsäuren zur Diagnose und Behandlung von viralen und neoplastischen Erkrankungen
US6162600A (en) Indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
EP2327420A2 (de) Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE3504940C2 (de) Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
EP1181381B1 (de) Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus
DE10122451A1 (de) Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
CN110075131B (zh) 寨卡病毒减毒株在治疗脑胶质瘤中的应用
CN109700957A (zh) 一种治疗犬螨虫病的阿维菌素中草药提取物乳膏剂及其制备方法
EP1289548B1 (de) Mittel zur stimulation des immunsystems
DE102005007690A1 (de) Mittel zur Erhöhung der Tumorrestistenz des Organismus
Li et al. Mesenchymal stem cells eliminate pulmonary bacterial infection by recruiting CXCR3~+ regulatory T cells to suppress inflammatory responses
CN117860800A (zh) 一种葫芦茶提取物及其在制备抗i型单纯疱疹病毒药物中的应用
DE10116594A1 (de) Künstliche Chromosomen, die EHV-Sequenzen umfassen
CN111214472A (zh) 依诺沙星在预防和/或治疗黄病毒感染中的应用
EP0356900A2 (de) Verwendung von IFN-gamma enthaltenden Arzneimitteln zur Vorbeugung und Behandlung von durch primäre Immundefekte verursachte Krankheiten